Atara Biotherapeutics to Present Initial Efficacy and Additional Safety Results from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019 September 9, 2019 - NASDAQ Companies 0 » View More News for September 09, 2019
